-+ 0.00%
-+ 0.00%
-+ 0.00%

Serina Therapeutics Doses First Patient In Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson's Disease

Benzinga·02/24/2026 21:24:23
Listen to the news

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –

- Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ -

HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, today announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson's disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina anticipates that blinded review of safety and tolerability by the Safety Monitoring Committee from Cohort 1 will allow advancement to Cohort 2 in the third quarter of 2026.